Response to: Comment on “Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)” - Sumati Gupta; Umang Swami; Gliceida M Galarza Fortuna (Journal for ImmunoTherapy of Cancer)